Assessment of melanoma patients receiving CII through assessing CTC and cfNA to assess multimodality treatments in blood and urine of melanoma patients. Using modern approaches of blood biopsy interrogation we are assessing patient responses to approved CII and new CII and targeted therapeutics in melanoma. Objective is to monitor patients during longitudinal treatment follow up with realtime blood biopsies using multiplatform assays (mutation, methylation, miRNA).

JWCI translational molecular medicine researcher working